2007 Access Data Safety 
Cannabis Law Report
JANUARY 23, 2022
ciency illnesses, congenital metabolic defects, hemoglobinopathies, and myelodysplastic and myeloproliferative syndromes (Weisdorf, 2007). GVHD is currently managed with a host of immune-suppressing drugs that support the body’s uptake of the donated tissue (Shlomchik, 2007). 2007) ‘GVHD—The Nuts and Bolts’, Hematology.
Cannabis Law Report
OCTOBER 29, 2019
ElleVet Sciences is pleased to announce the results and publication of the first safety study on the use of hemp CBD/CBDA. The 12-week safety study, conducted by Dr. Joseph Wakshlag, DVM, Ph.D., This data gives us confidence in the use of both the chew and the oils as effective means for delivering CBD to your pet.”.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
FEBRUARY 2, 2022
CLARA uses natural language processing to perform contextual analysis, incorporating structured, semi-structured and unstructured data into its AI analysis. The National Highway Traffic Safety Administration (NHTSA) reports that the percentage of fatally injured drivers who tested positive for drugs increased from 25% in 2007 to 42% in 2016.
Cannabis Law Report
MAY 26, 2022
was published in the Journal of Safety Research and made available online on May 18. Journal of Safety Research. The objective of the current study was to assess the ease of access to marijuana by underage patrons at recreational marijuana outlets in California, where recreational marijuana was legalized in 2016.
Cannabis Law Report
NOVEMBER 24, 2021
However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. At the same time, the outlook on cannabis research data is largely positive. Refractory paediatric epilepsy.
Cannabis Law Report
APRIL 8, 2022
The FDA formally decided to open the door to psychedelic research in human participants, and later accepted MAPS’ Phase 1 MDMA safety and tolerance study protocol. MAPS completed the first Phase 1 safety study with MDMA and resumed working on a protocol for anxiety associated with cancer. Rick Doblin, Ph.D.,
Greencamp
APRIL 23, 2019
Multiple sclerosis qualifies one for getting access to medical cannabis in some states in the US. In 2005, a group of researchers was looking into the effectiveness and long-term safety of tetrahydrocannabinol for MS. However, not all patients respond to these treatments well enough, and some don’t respond at all.
Expert insights. Personalized for you.
52 
Let's personalize your content